RCRachel Y. Cheong

Rachel Y. Cheong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachel Y. Cheong has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Åsa Petersén

    Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, 22184, Lund, Sweden

    8 shared publications
  • Deniz Kirik

    Brain Repair and Imaging in Neural Systems (BRAINS) Unit, Department of Experimental Medical Science Lund University Lund Sweden

    5 shared publications
  • Istvan M. Abraham

    Centre for Neuroendocrinology and Department of Physiology Otago School of Medical Sciences University of Otago Dunedin New Zealand

    5 shared publications
  • Allan Edward Herbison

    Department of Physiology, Development and Neuroscience, University of Cambridge

    4 shared publications
  • Åsa Petersén

    Translational Neuroendocrine Research Unit, Department of Experimental Medical Science Lund University Lund Sweden

    4 shared publications
  • Andrea Kwakowsky

    Pharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials, Galway Neuroscience Centre, University of Galway, Galway, Ireland

    3 shared publications

Latest Publications

  • Open Access

    Comparison of efficacy between subcutaneous and intravenous application of moss‐aGal in the mouse model of Fabry disease

    by Paulina Dabrowska‐Schlepp, Andreas Busch, Jin‐Song Shen, Rachel Y. Cheong, Lone Bruhn Madsen, Daniel Mascher, Raphael Schiffmann, Andreas Schaaf

    Fabry disease (FD, OMIM 301500) is a rare X‐linked inherited lysosomal storage disorder associated with reduced activities of α‐galactosidase A (aGal, EC 3.2.1.22). The current standard of care for FD is based on enzyme replacement therapy (ERT), in which a recombinantly produced version of αGal is intravenously (iv) applied to Fabry patients in biweekly intervals. Though the iv application is clinically efficacious, periodical infusions are inconvenient, time‐ and resource‐consuming and they negatively impact the patients’ quality of life. Subcutaneous (sc) injection, in contrast, is an established route of administration for treatment of chronic conditions. It opens the beneficial option of self‐administration, thereby improving patients’ quality of life and at the same time reducing treatment costs. We have previously shown that Moss‐α‐Galactosidase (moss‐aGal), recombinantly produced in the moss Physcomitrium patens, is efficient in degrading accumulated Gb3 in target organs of murine model of FD and in the phase I clinical study, we obtained first efficacy evidence in human patients following single iv infusion. Here, we tested the efficacy of subcutaneous administration of moss‐aGal and compared it with the results observed following iv infusion in Fabry mice. The obtained findings demonstrate that subcutaneously applied moss‐aGal is correctly transported to target organs and efficacious in degrading Gb3 deposits there and thus suggest the possibility of using this route of administration for therapy of Fabry disease.


  • Open Access

    Effects of mutant huntingtin in oxytocin neurons on non‐motor features of Huntington's disease

    by Sofia Bergh, Sanaz Gabery, Simone Tonetto, Deniz Kirik, Åsa Petersén, Rachel Y. Cheong

    Background: Early non‐motor features including anxiety, depression and altered social cognition are present in Huntington's disease (HD). The underlying neurobiological mechanisms are not known. Oxytocin (OXT) is involved in the regulation of emotion, social cognition and metabolism, and our previous work showed that the OXT system is affected early in HD. The aim of the study was to investigate the potential causal relationship between the selective expression of mutant huntingtin (mHTT) in OXT neurons and the development of non‐motor features and neuropathology.Methods: To express mHTT only in OXT neurons, we used a novel flex‐switch adeno‐associated viral vector design to selectively express either mHTT or wild‐type HTT in the paraventricular nucleus of the hypothalamus using OXT‐Cre‐recombinase mice. We also performed a mirror experiment to selectively delete mHTT in OXT neurons using the BACHD mouse model. Mice underwent a battery of behavioural tests to assess psychiatric and social behaviours 3 months post‐injection or at 2 months of age, respectively. Post‐mortem analyses were performed to assess the effects on the OXT system.Results: Our results show that selective expression of mHTT in OXT neurons was associated with the formation of mHTT inclusions and a 26% reduction of OXT‐immunopositive neurons as well as increased anxiety‐like behaviours compared with uninjected mice. However, selective deletion of mHTT from OXT neurons alone was not sufficient to alter the metabolic and psychiatric phenotype of the BACHD mice at this early time point.Conclusions: Our results indicate that mHTT expression can exert cell‐autonomous toxic effects on OXT neurons without affecting the non‐motor phenotype at early time points in mice.


  • Open Access

    Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks

    by Sabina Marciano, Tudor M. Ionescu, Ran Sing Saw, Rachel Y. Cheong, Deniz Kirik, Andreas Maurer, Bernd J. Pichler, Kristina Herfert

    Receptors, transporters, and ion channels are important targets for therapy development in neurological diseases, but their mechanistic role in pathogenesis is often poorly understood. Gene editing and in vivo imaging approaches will help to identify the molecular and functional role of these targets and the consequence of their regional dysfunction on the whole-brain level. We combine CRISPR-Cas9 gene editing with in vivo positron emission tomography (PET) and functional MRI (fMRI) to investigate the direct link between genes, molecules, and the brain connectome. The extensive knowledge of theSlc18a2gene encoding the vesicular monoamine transporter (VMAT2), involved in the storage and release of dopamine, makes it an excellent target for studying the gene network relationships while structurally preserving neuronal integrity and function. We edited theSlc18a2in the substantia nigra pars compacta of adult rats and used in vivo molecular imaging besides behavioral, histological, and biochemical assessments to characterize the CRISPR-Cas9–mediated VMAT2 knockdown. Simultaneous PET/fMRI was performed to investigate molecular and functional brain alterations. We found that stage-specific adaptations of brain functional connectivity follow the selective impairment of presynaptic dopamine storage and release. Our study reveals that recruiting different brain networks is an early response to the dopaminergic dysfunction preceding neuronal cell loss. Our combinatorial approach is a tool to investigate the impact of specific genes on brain molecular and functional dynamics, which will help to develop tailored therapies for normalizing brain function.


  • Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients

    by Marie N.N. Hellem, Rachel Y. Cheong, Simone Tonetto, Tua Vinther-Jensen, Rebecca K. Hendel, Ida U. Larsen, Troels T. Nielsen, Lena E. Hjermind, Asmus Vogel, Esben Budtz-Jørgensen, et al.


  • Open Access

    Effects of mutant huntingtin inactivation on Huntington disease‐related behaviours in the BACHD mouse model

    by Rachel Y. Cheong, Barbara Baldo, Muhammad U. Sajjad, Deniz Kirik, Åsa Petersén

    Aims: Huntington disease (HD) is a fatal neurodegenerative disorder with no disease‐modifying treatments approved so far. Ongoing clinical trials are attempting to reduce huntingtin (HTT) expression in the central nervous system (CNS) using different strategies. Yet, the distribution and timing of HTT‐lowering therapies required for a beneficial clinical effect is less clear. Here, we investigated whether HD‐related behaviours could be prevented by inactivating mutant HTT at different disease stages and to varying degrees in an experimental model.Methods: We generated mutant BACHD mice with either a widespread or circuit‐specific inactivation of mutant HTT by using Cre recombinase (Cre) under the nestin promoter or the adenosine A2A receptor promoter respectively. We also simulated a clinical gene therapy scenario with allele‐specific HTT targeting by injections of recombinant adeno‐associated viral (rAAV) vectors expressing Cre into the striatum of adult BACHD mice. All mice were assessed using behavioural tests to investigate motor, metabolic and psychiatric outcome measures at 4–6 months of age.Results: While motor deficits, body weight changes, anxiety and depressive‐like behaviours are present in BACHD mice, early widespread CNS inactivation during development significantly improves rotarod performance, body weight changes and depressive‐like behaviour. However, conditional circuit‐wide mutant HTT deletion from the indirect striatal pathway during development and focal striatal‐specific deletion in adulthood failed to rescue any of the HD‐related behaviours.Conclusions: Our results indicate that widespread targeting and the timing of interventions aimed at reducing mutant HTT are important factors to consider when developing disease‐modifying therapies for HD.


  • Open Access

    The Role of Hypothalamic Pathology for Non-Motor Features of Huntington’s Disease

    by Rachel Y. Cheong, Sanaz Gabery, Åsa Petersén

    Huntington’s disease (HD) is a fatal genetic neurodegenerative disorder. It has mainly been considered a movement disorder with cognitive symptoms and these features have been associated with pathology of the striatum and cerebral cortex. Importantl


  • Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity

    by S. Fjalldal, C. Follin, S. Gabery, P. C. Sundgren, I. M. Björkman-Burtscher, J. Lätt, P. Mannfolk, C. H. Nordström, L. Rylander, B. Ekman, et al.

    Hypothalamic obesity (HO) occurs in 50% of patients with the pituitary tumor craniopharyngioma (CP). Attempts have been made to predict the risk of HO based on hypothalamic (HT) damage on magnetic resonance imaging (MRI), but none have included volumetry. We performed qualitative and quantitative volumetric analyses of HT damage. The results were explored in relation to feeding related peptides and body fat. A cross-sectional study of childhood onset CPs involving 3 Tesla MRI, was performed at median 22 years after first operation; 41 CPs, median age 35 (range: 17–56), of whom 23 had HT damage, were compared to 32 controls. After exclusions, 35 patients and 31 controls remained in the MRI study. Main outcome measures were the relation of metabolic parameters to HT volume and qualitative analyses of HT damage. Metabolic parameters scored persistently very high in vascular risk particularly among HT damaged patients. Patients had smaller HT volumes compared to controls 769 (35–1168) mm3 vs. 879 (775–1086) mm3; P < 0.001. HT volume correlated negatively with fat mass and leptin among CP patients (rs = −0.67; P < .001; rs = −0.53; P = 0.001), and explained 39% of the variation in fat mass. For every 100 mm3 increase in HT volume fat mass decreased by 2.7 kg (95% CI: 1.5–3.9; P < 0.001). Qualitative assessments revealed HT damage in three out of six patients with normal volumetry, but HT damage according to operation records. A decrease in HT volume was associated with an increase in fat mass and leptin. We present a method with a high inter-rater reliability (0.94) that can be applied by nonradiologists for the assessment of HT damage. The method may be valuable in the risk assessment of diseases involving the HT.


  • Laminin α1 reduces muscular dystrophy in dy mice

    by Kinga I. Gawlik, Vahid M. Harandi, Rachel Y. Cheong, Åsa Petersén, Madeleine Durbeej


  • Open Access

    Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition

    by Florian A. Siebzehnrübl, Kerstin A. Raber, Yvonne K. Urbach, Anja Schulze-Krebs, Fabio Canneva, Sandra Moceri, Johanna Habermeyer, Dalila Achoui, Bhavana Gupta, Dennis A. Steindler, et al.

    Significance: In Huntington disease (HD) gene carriers the disease-causing mutant Huntingtin (m HTT ) is already present during early developmental stages, but, surprisingly, HD patients develop clinical symptoms only many years later. While a developmental role of Huntingtin has been described, so far new therapeutic approaches targeting those early neurodevelopmental processes are lacking. Here, we show that behavioral, cellular, and molecular changes associated with m HTT in the postnatal period of genetic animal models of HD can be reverted using low-dose treatment with a histone deacetylation inhibitor. Our findings support a neurodevelopmental basis for HD and provide proof of concept that pre-HD symptoms, including aberrant neuronal differentiation, are reversible by early therapeutic intervention in vivo.